Clinical Trials Logo
  1. Home
  2. Coronavirus Disease 2019
  3. NCT04280913
  4. Details
NCT04280913 Clinical Trial

Clinical Outcomes of Patients With COVID19

Coronavirus Disease 2019 Clinical Trial

Official title:
Clinical Outcomes of Hospitalized Patients With Coronavirus Disease 2019

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT04280913
Other study ID # GZHZ-COVID19
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date February 22, 2020
Est. completion date March 31, 2020

Study information
Verified date March 2020
Source Guangzhou Institute of Respiratory Disease
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

As of February 17th, 2020, China has 70635 confirmed cases of coronavirus disease 2019 (COVID-19), including 1772 deaths. Human-to-human spread of virus via respiratory droplets is currently considered to be the main route of transmission. The number of patients increased rapidly but the impact factors of clinical outcomes among hospitalized patients are still unclear.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date March 31, 2020
Est. primary completion date March 31, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Hospitalized patients with COVID19

Exclusion Criteria:

- Suspected patients with COVID19, not confirmed by the laboratory

- Patients who are refused to receive medical treatments

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• retrospective analysis
The investigators retrospectively analyzed the hospitalized patients with COVID-19.

Locations
Country Name City State
China HuiZhou Municipal Central Hospital Huizhou Guangdong

Sponsors (2)
Lead Sponsor Collaborator
Guangzhou Institute of Respiratory Disease Huizhou Municipal Central Hospital

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Time to negative conversion of severe acute respiratory syndrome coronavirus 2 The primary outcome is the time to negative conversion of coronavirus 1 month
Secondary Length of stay in hospital The time of hospitalization. 1 month
Secondary Survival The rate of survival within hospitalization of these patients will be tracked. 1 month
Secondary Intubation The rate of intubation within hospitalization of these patients will be tracked. 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT05091411 - Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells) Phase 3
Completed NCT05107375 - Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine Phase 3
Active, not recruiting NCT05128643 - Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell) Phase 3
Completed NCT04988217 - Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19) Phase 1/Phase 2
Completed NCT04579393 - Fostamatinib for Hospitalized Adults With COVID-19 Phase 2
Withdrawn NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Recruiting NCT05047783 - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Phase 2
Completed NCT04646044 - A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 Phase 1
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Recruiting NCT05092568 - Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
Completed NCT05364268 - Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
Completed NCT06189040 - Immunogenicity After COVID-19 Vaccines in Adapted Schedules Phase 4
Recruiting NCT04401436 - COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
Not yet recruiting NCT04395742 - 1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
Recruiting NCT04388631 - Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.
Completed NCT05501288 - Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019 N/A
Active, not recruiting NCT05216471 - Identify Coronavirus Disease by Chest X-ray
Terminated NCT04672564 - Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients Phase 3
Completed NCT04967781 - Autoimmunity Contributes to the Severe Progression of COVID-19
Completed NCT04678830 - Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19 Phase 2